Suspect Product Under DSCSA: How a Drug Track and Trace System Supports Investigation and FDA Notification
By Covectra | Posted on November 19, 2026

A drug track and trace system helps manufacturers investigate suspect product by storing the serialization and transaction data DSCSA requires them to check during an investigation. That data connects the product identifier on each package to a specific transaction. When it can be retrieved quickly, a manufacturer can quarantine the product, verify it, and decide within the law’s 24-hour windows whether FDA and trading partners need to be notified.
A suspect product finding starts a sequence that ends only when FDA agrees a notification can be closed. Each step has its own deadline and documentation, and the records must be kept for six years. The speed of each step depends on how complete and accessible the manufacturer’s serialization data is when the first question comes in.
Key Takeaways
- Suspect and illegitimate are separate findings. Only illegitimate product, or a manufacturer’s high-risk finding, requires a 24-hour notice to FDA.
- Quarantine comes first. Suspect product stays apart from saleable stock until it is cleared or dispositioned.
- Serial-level data drives the investigation. Manufacturers verify the NDC, serial number, lot, and expiration date they assigned to each package.
- FDA must respond before a notification closes. Trading partners are told a notification has ended only after the FDA answers the termination request.
Suspect Product, Illegitimate Product, and High Risk Under DSCSA
DSCSA sorts questionable product into three categories, and each one sets different obligations for a manufacturer.
- Suspect product. There is reason to believe the product is potentially counterfeit, diverted, stolen, or the subject of a fraudulent transaction. It also covers product that may be intentionally adulterated or otherwise unfit in ways that could cause serious adverse health consequences. Suspect product requires quarantine and investigation, but not FDA notification.
- Illegitimate product. Credible evidence shows the product falls into one of those categories. The manufacturer must notify FDA and immediate trading partners within 24 hours, according to FDA’s suspect product and notification guidance.
- High risk of illegitimacy. This category applies only to manufacturers. A manufacturer that determines, or is told, that a product carries a high risk of being illegitimate must notify FDA within 24 hours, for example while it waits for lab confirmation of a suspected counterfeit.
Reading tip: For a closer look at warning signs and packaging authentication methods, read section 3 of our guide to Pharmaceutical Supply Chain Security.
What DSCSA Requires Once a Product Is Suspect
The statute sets the same sequence for every manufacturer, and FDA’s Verification Systems guidance describes what each step should include. A product can become suspect through internal review, an FDA request, or a trading partner’s concern. A verification request with a product identifier that doesn’t match the manufacturer’s records also makes the product suspect.
Step 1: Quarantine the Product
Suspect product must be kept apart from product intended for distribution. FDA accepts physical separation, electronic quarantine in the manufacturer’s systems, or both, and encourages using both when possible. It also recommends giving release authority to a specific person, such as a member of the quality unit.
Step 2: Investigate With Trading Partners
For a manufacturer, the statute requires two checks:
- Validate the transaction records by confirming the NDC and lot number match the suspect product.
- Verify the product identifier by confirming the NDC, serial number, lot, and expiration date match what the manufacturer assigned.
FDA also expects active communication with trading partners, lab testing where needed, and an analysis of how the product entered the supply chain.
Step 3: Clear the Product or Treat It as Illegitimate
Cleared product can be distributed again. A cleared product notification is required only if FDA had requested verification of that product. An illegitimate product determination requires the manufacturer to:
- Notify FDA within 24 hours on Form FDA 3911, which generates an incident number for all follow-up
- Notify immediate trading partners that may have received the product within 24 hours
- Quarantine and disposition the product, and help trading partners disposition product they hold
By the numbers: FDA’s 2025 paperwork estimate projects about 14,100 Form FDA 3911 notifications a year from roughly 500 trading partners. These are planning assumptions, not a count of filings. (Federal Register, May 2025)
Step 4: Terminate the Notification With FDA
A notification stays open until FDA responds to a termination request. The manufacturer submits the request on Form FDA 3911 with the incident number and explains why notification is no longer needed. Once FDA responds, the manufacturer tells the trading partners it originally notified. This termination process is the one binding part of FDA’s suspect product guidance.
DSCSA Deadlines at a Glance
| Obligation | Deadline |
| Notify FDA and immediate trading partners of illegitimate product | 24 hours after the determination |
| Notify FDA of high risk of illegitimacy (manufacturers) | 24 hours after determining or being notified |
| Respond to a trading partner’s verification request | 24 hours after receiving it |
| Provide transaction information to FDA or officials during an investigation | 1 business day, not to exceed 48 hours |
| Keep investigation and disposition records | At least 6 years |
How a Drug Track and Trace System Supports Investigation and FDA Notification
Under DSCSA’s enhanced requirements, transaction information includes the product identifier for each package. A drug track and trace system that captures that link between serial number and shipment supplies the answers each deadline requires.
Verifying Packages at the Serial Number Level
In April 2025, FDA warned that counterfeit Ozempic 1 mg had entered the U.S. drug supply chain, identified by lot PAR0362 and serial numbers starting with 51746517. The lot number itself was authentic, Novo Nordisk said. A lot-level check would have passed those units, while the serial numbers identified them as counterfeit.
Finding the Trading Partners to Notify
Shipment records linked to serial numbers show which customers received which packages. That limits the 24-hour notification to the partners who may have received the product.
Holding Product Electronically
FDA describes electronic quarantine as a system designation that prevents sale or distribution. It also recommends flagging any newly received product whose serial number matches product already found to be illegitimate. Both depend on product status being stored at the package level.
Meeting Records Requests on Time
When FDA or a state official requests transaction information during an investigation, the manufacturer has one business day to respond. Data searchable by serial number, lot, or customer makes that deadline manageable.
Suspect Product Investigation Support From Covectra
Covectra is a single-source serialization provider, covering cloud traceability, authentication, and implementation services. Four parts apply to suspect product investigations:
- Serial event history. AuthentiTrack serialization and traceability is EPCIS certified and built around a serial event history repository. Its secure data gateway connects CMO and brand owner systems, so contract manufacturer data is available when an investigation needs it.
- Verification responses. The Verification Router Service checks each item against GTIN, serial number, lot, and expiration date, and can tell the requester when a product is suspect or recalled.
- Packaging authentication. StellaGuard smart security labels pair a serialized QR code with a patented holographic star pattern that inspectors can authenticate with any smartphone.
- Implementation. The company’s pharmaceutical serialization services include serialization engineering, systems integration, and implementation support.
DSCSA Suspect Product FAQs for Pharmaceutical Manufacturers
Do we have to notify FDA every time we find a suspect product?
No. Suspect product requires quarantine and investigation. FDA notification is required for illegitimate product, for a manufacturer’s high-risk finding, or for cleared product that FDA had asked to verify.
Can our wholesalers rely on our investigation results?
Yes. FDA considers it appropriate for trading partners in a coordinated investigation to rely on the manufacturer’s results. FDA also expects manufacturers to share those results.
How long does FDA take to close a notification?
FDA intends to respond to termination requests within 10 business days but may need longer. If a delay could contribute to a drug shortage, say so in the request.
What records do we need to keep from a suspect product investigation?
Keep investigation and disposition records for at least six years. FDA expects records for cleared product too, with an explanation of how the decision was reached.
Test Your Suspect Product Readiness
The first hours of an investigation decide whether the 24-hour and one-business-day deadlines are met. Three questions show where an investigation could stall:
- Can your team pull the transaction records for a single serial number without a manual search?
- Do you know which customers received a given lot or serial range?
- If a CMO packaged the product, can you get its serialization data when an investigation starts?
A serialization review with Covectra walks through those questions against your current setup and identifies what would need to change.
Request a Serialization Review
Related Reading
- Saleable Returns Verification: What Manufacturers Owe Wholesalers
- Serialized Traceability: Closing the Gaps in the Pharma Supply Chain
- What Pharmaceutical Traceability Software Should Deliver Across the Supply Chain
